Yangtze River Pharmaceutical Group Co., Ltd.

Tianjin North Pharma Sci-tech Co., Ltd

Reach Surgical Inc.

Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Tasly Holding Group Co., Ltd.

Tianjin Tasly Group Co., Ltd.

Yangtze River Pharmacuetical (group) Co., Ltd.

Yangtze River Pharmaceutical Co., Ltd.

Yongfeng Wang

Kejun Zhao

Guocheng Wang

Wei Zhou

Yunrong Jing

Xianfeng Lu

Haibo Zhang

Gan Zhang

Lingwu Chen

Huixing Liang

Lianyong Shi

Hongpeng Luo

Dan Fei

The disclosure relates to a surgical instrument and discloses a flexible drive member, an end-effector, and a surgical instrument. The flexible drive member includes a distal portion, a proximal portion, and a bendable portion therebetween, wherein the bendable portion includes a plurality of wire bundles extending in the length direction of the flexible drive member, and a flexible casing enclosing the plurality of wire bundles. In the technical solutions of the disclosure, the bendable portion is provided with some rigidity and flexibility due to the plurality of wire bundles, and the flexibly casing can fix the plurality of wire bundles relatively and can alleviate friction rate of the surface of the flexible drive member and further improve the rigidity of the flexible drive member.

Flexible drive member, end-effector, and surgical instrument using the same

Disclosed are an articulating assembly and a surgical instrument using the same. The articulating assembly includes a driver assembly configured to articulate an end effector of said surgical instrument, where said driver assembly includes: a screw portion rotatably mounted in a stationary handle of said surgical instrument, an axis of which is parallel to an axis of an elongated portion of said surgical instrument, wherein said screw portion is provided with at least two segments with opposite threads; two articulation plates in connection with said two thread segments, respectively, wherein a distal end of each articulation plate is in connection with said end effector of said surgical instrument; and a rotating sleeve coaxially sheathed on said screw portion so as to be in connection therewith through a gear assembly when being located at an articulation position.

Articulating assembly and surgical instrument using the same

The present invention provides taxanes compounds with a formula (I) or formula (II) structure, a method for preparing the compounds, as well as the use of the compositions containing the compounds, pharmaceutically acceptable salts and solvates thereof as active ingredients in manufacturing oral antitumor medicaments,  In formula (I), Ris &#x2014;COR, &#x2014;COORor &#x2014;CONRR; Ris a C1-C6 alkyl, a C1-C6 alkenyl, a substituted hydrocarbon group, a heterocyclic group, an aromatic group or a substituted aromatic group; Ris &#x2014;OR, &#x2014;OCOOR, &#x2014;OCOSRor &#x2014;OCONRR; Ris &#x2014;OR, &#x2014;OCOOR, &#x2014;OCOSR, &#x2014;OCONRRor H; wherein, Ris a C1-C6 alkyl, a C1-C6 alkenyl, a C1-C6 alkynyl, a substituted hydrocarbon group, an aromatic group or a heterocyclic group; Rand Rare respectively hydrogen, a hydrocarbon group, a substituted hydrocarbon group or a heterocyclic group. In formula (II), Ris &#x2014;CORor &#x2014;COOR; Ris an aromatic group; Ris &#x2014;OR; wherein, Ris a C1-C6 alkyl, a C1-C6 alkenyl, a C1-C6 alkynyl, a substituted hydrocarbon group, an aromatic group or a heterocyclic group.

Taxanes compounds, preparation method therefor, and uses thereof

Provided are taxanes compounds having the structure of formula I, preparation method thereof, and uses of compositions having the compound, pharmaceutical salts and solvates thereof as active ingredients in the preparation of oral antitumor drugs. In the formula, Ris &#x2014;COR, &#x2014;COOR, and &#x2014;CONRR; Ris C1-C6 alkyl, C1-C6 alkenyl group, a substituted hydrocarbon group, a heterocyclic group, an aromatic group or a substituted aromatic group; Ris &#x2014;OR, &#x2014;OCOOR, &#x2014;OCOSR, and &#x2014;OCONRR; Ris &#x2014;OR, &#x2014;OCOOR, &#x2014;OCOSR, &#x2014;OCONRR, H, and OH; Ris C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl group, a substituted hydrocarbon group, an aromatic group or a heterocyclic group; and Rand Rare respectively hydrogen, a hydrocarbon group, a substituted hydrocarbon group or a heterocyclic group. 

Taxane compound, and preparation method and use thereof

The present application discloses an A-type polymorphic substance of yonkenafil hydrochloride and a preparation method, a composition and use thereof. The powder diffraction pattern of the A-type polymorphic substance of yonkenafil hydrochloride comprises diffraction peaks at three or more 2&#x3b8; values selected from: 8.4&#xb1;0.2&#xb0;, 11.3&#xb1;0.2&#xb0;, 13.9&#xb1;0.2&#xb0;, 14.2&#xb1;0.2&#xb0;, 14.7&#xb1;0.2&#xb0;, 16.8&#xb1;0.2&#xb0;, 17.1&#xb1;0.2&#xb0;, 19.7&#xb1;0.2&#xb0;, 21.0&#xb1;0.2&#xb0;, 21.7&#xb1;0.2&#xb0;, 22.4&#xb1;0.2&#xb0;, 23.3&#xb1;0.2&#xb0;, 23.8&#xb1;0.2&#xb0;, 26.8&#xb1;0.2&#xb0;, 27.5&#xb1;0.2&#xb0;, 28.0&#xb1;0.2&#xb0;.

Polymorphic substance of yonkenafil hydrochloride, preparation method therefor, and composition and use thereof

The present invention relates to a controlled release system, in particular to a controlled release system containing temozolomide.

Controlled releases system containing temozolomide

The invention relates to the compounds of formula I, their preparation and the pharmaceutical compositions containing the compounds. The invention also relates to the use of the compounds of formula I in preparing medicines, which can treat sexual dysfunction of animals including human (male and female), especially erectile dysfunction of male and the diseases in which the function of phospholipase 5 (cGMP PDE5) is involved. 

2-Substituted phenyl-5,7-dihydrocarbyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof

2-Substituted phenyl-5, 7-dihydrocarbyl-3, 7-dihydropyrrolo [2, 3-D] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof

Process for making substituted pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of phosphodiesterase 5

The present invention discloses general formula I of Temozolomide-8-carboxylate compounds, the process for preparation, pharmaceutical compositions comprising the compounds and the use of the compounds and pharmaceutical compositions for the manufacture of an antitumor medicament. The said pharmaceutical composition comprises one or more general formula I Temozolomide-8-carboxylate compounds as active ingredient, together with conventional pharmaceutical carriers. The composition also comprises one or more pharmaceutically acceptable acidic material, optionally second or tertiary alcohol or ester or ether derivatives thereof. The said pharmaceutical composition can be made into various common formulations, particularly oral formulations as well as topically transdermal patches. The present invention also discloses the application of the compounds and the compositions to treat tumor.

Growing community of inventors

Tianjin, China

Yongfeng Wang